IGF2BP1 in 17q-gain cooperates with MYCN to regulate purine biosynthesis and immunotherapy efficacy in neuroblastoma
Proceedings of the National Academy of Sciences, Volume 123, Issue 41, October 2026. SignificanceChildren with high-risk neuroblastoma, a devastating nerve cell cancer, frequently exhibit two specific genetic abnormalities: MYCN (Neuroblastoma-derived MYC) amplification and chromosomal 17q gain. How these alterations cooperate to drive ...Read More
bubmagOctober 9, 2026